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Abstract:  
The World Health Organization inspires the use of fixed dose combination (FDC) of rifampicin combination used 
with isoniazid, isoniazid with pyrazinamide or pyrazinamide with ethambutol for the treatment of tuberculosis. Hence, 
it’s used worldwide for reducing the risk of emerging drug resistance. Rifampicin is one of the potent and broad 
spectrum antibiotics against bacterial pathogen. It works by inhibits the DNA dependent RNA polymerase activity by 
forming stable complex with enzyme. Here, the polymorphic form of rifampicin is describe by thermal study of 
rifampicin. The thermal behavior of two polymorphic forms of rifampicin was studied by DSC, FTIR, TGA, PXRD. 
The thermoanalytical results clearly showed the differences between the two crystalline forms. Polymorph I was the 
most thermally stable form and polymorph II was meta stable. On the DSC study of rifampicin it was shows the 
difference between both form on basis of melting point and exothermic and endothermic peak. The DSC curve of form 
I RMP shows the exothermic peak at the temperature between  240- 420ºc and form II RMP shows the endothermic 
peak at temperature range between 183-188ºc. By using the FTIR spectrum of form I RMP, it was shown that the 
absorption bands at approximately 3400 cm−1, 1722 cm−1, 1643 cm−1, for the OH of the chain loop group, acetyl group, 
furanone group sufficient to characterize form I of RMP and form II of RMP, it was shown that the absorption bands 
at 3356 cm−1 ,1732 cm−1, 1714 cm−1 , for the OH group, furanone group and acetyl group are sufficient to differentiate 
form I and form II rifampicin. In TGA analysis of RMP both polymorphs shows TGA curve form I occurred at the 
temperature 224.17 ºC and form II showed the temperature at 194.04 ºC. Powder X-ray diffraction was used to test 
the polymorphic forms of solid-state rifampicin. 
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INTRODUCTION: 
Tuberculosis is deadly infectious disease cause in the 
world today. An important thought in the treatment of 
tuberculosis is the reality that the aetiological agents, 
Mycobacterium tuberculosis (MBT) and 
mycobacterium avium complex have the capable to 
preserve intracellularly in the host macrophages for 
longer time period [1]. Actually, they are intracellular 
parasites that can grow firstly in macrophages, that can 
produce the efficacy of antimicrobial agents that are 
having a lower ability to penetrate into the phagocytic 
cells. In the treatment of tuberculosis the oral 
administration of rifampicin, isoniazid, ethambutol 
and pyrazinamide taken for a period of 6-12 months. 
These drugs are relatively toxic and cause several 
adverse effects. Moreover, drug resistance can occur 
when treatment is not followed to completion [2]. 
Currently the drug used in first line treatment of 
tuberculosis are rifampicin, isoniazid, ethambutol, 
streptomycin, pyrazinamide, fluoroquinolones and 
second line drugs are amikacin, cycloserine, 
capreomycin, cycloserine, kanamycin, ofloxacin, 
levofloxacin, para-amino-salicylic acid [1]. 
 
Who approved FDC drug for tuberculosis:  
First line TB drugs: Isoniazid, rifampicin, 
pyrazinamide, ethambutol. 
Second line TB drugs:  Fluroquinolones, amikacin, 
cycloserine, capreomycin, cycloserine [3]. 
 
Table 1 : Fixed-dose combinations from the WHO Model List of medicine 
 
Drug Dose form Strength for daily use Strength for 
intermittent use 3 times 
per weak 
Rifampicin + 
isoniazid(RH) 
Tablet  
 
Tablet or pack of granules 
150 mg + 75 mg 
 
60 mg +30 mg 
150mg +150mg 
 
60mg+60mg 
Ethambutol +isoniazid 
(EH) 
Tablet  400 mg +150 mg - 
Isoniazid + thioacetazone 
(HT) 
Tablet  100 mg + 50 mg 
300 mg + 150 mg 
- 
Rifampicin + isoniazid + 
pyrazinamide  
Tablet  
 
 
Tablet or pack of granules 
150 mg + 75 mg + 400 mg 
 
60 mg + 30 mg + 150 mg 
150 mg + 150 mg + 500 
mg 
 
- 
Rifampicin + isoniazid + 
pyrazinamide + 
ethambutol (RHPE) 
Tablet  150 mg + 75 mg + 400 mg 
+ 275 mg  
 
 
RIFAMPICIN : 
form Rifampicin  is evaluate as the main constituent 
for the treatment of tuberculosis in concurrence with 
other first-line anti-TB drugs, which is being used both 
in the severe phase as well as in the maintenance of 
treatment. Rifampicin is a semisynthetic antibiotic- 
family of rifamycins, a rifamycin B derivative - create 
by strains of Nocardia  mediterranei,  discovered in the 
1960s. 
 
A rifampicin is geting from streptomyces mediterranei 
and it is a semisynthetic antibiotic It is a large 
spectrum of antibiotic, used antagonistic towards the 
some forms of mycobacterium [4]. It is sensitive to 
microorganisms which inhibits DNA- dependent RNA 
polymerase activity by forming a stable complex with 
the enzyme. It delay the evolution of RNA synthesis. 
Rifampicin has bactericidal effect and take action on 
both intracellular and extracellular organisms. 
 
Rifampicin is a complex molecule shows the different 
formation due to interaction between their functional 
group, it has stimulating the different crystal 
morphologies. It exhibit red brown crystalline powder 
because of the dissimilar crystal morphologies and 
rifampicin shows polymorphism. It is existing two 
polymorphic form, form I and form II. Form I is stable 
and form II is meta stable. Besides these two 
polymorphic forms, RMP is found as hydrates 
(monohydrate, dihydrate and pentahydrate), as 
solvates and also in amorphous. 
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                                                   Table 2 : physical characteristics of rifampicin 
Parameters Result 
Color Red to orange platelets from acetone and red-brown crystalline 
powder 
Molecular formula C43H58N4O12 
Molecular weight 822.94 g/mol 
IUPAC name 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,20,22-
heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-
(epoxypentadecane[1,11,13]trienimino)naptho[2,1-b]furan-
1,11(2H)-dione21-acetate 
 
Melting point  Polymorph I - 245- 260˚c 
Polymorph II - 183-188 °C 
BCS class Class II  
Half life 3.35 hour 
Protein binding 89 % 
Water solubility  1400 mg/L 
LogP  2.77 
pKa  6.9 (Acidic)   
7.53 (Basic) 
 
 
STRUCTURE :  
 
Fig. 1: Structure of Rifampicin [5,6] 
 
Mechanism of action:  
Rifampicin inhibits bacterial DNA-dependent RNA 
synthesis by inhibiting bacterial DNA-dependent 
RNA polymerase[5,6].  Rifampicin binds to the pocket 
of the RNA polymerase β subunit within the 
DNA/RNA channel, but away from the active site 
[7,8,9]. 
 
Pharmacokinetic of rifampicin:  
Absorption: Rifampicin go through quick and entire 
absorption after oral dose. Absorption is upgrade when 
the oral dose is taken on an empty stomach, as food 
may reduce the rate of absorption of rifampicin. 
Rifampicin absorption is especially responsive to 
changes in object formulation [10]. 
Distribution: 
Rifampicin go through broad distribution into most 
body tissues and fluids, including the cerebrospinal 
fluid. It has a unique property of penetrating 
intracellularly. The protein binding is around 80%. 
Rifampicin was detected in maternal milk and it 
crosses the placenta [11] 
. 
Metabolism and Elimination: 
Rifampicin is extensively eliminated by intestinal and 
hepatic metabolism and rapidly deacetylated. The drug 
and its metabolites are mostly eliminated in the bile 
and in stools. Rifampicin go through enterohepatic 
recirculation as its metabolites. At most a little amount 
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of the dose is eliminated in the urine 15-25 % 
providing the urine an orange color1 [12, 13]. 
 
Pharmacodynamic of rifampicin :  
Rifampicin that inhibits DNA-dependent RNA 
polymerase action in liable cells because it have 
antibiotic action [11] . It attach with bacterial RNA 
polymerase but does not stop the mammalian enzyme. 
It has a wide spectrum of action opposed to gram-
positive and gram-negative organisms which include 
Pseudomonas aeruginosa and Mycobacterium 
tuberculosis. Because of quick evolution of resistant 
bacteria. Its use is to restrict the treatment of 
mycobacterial infections and a small other sign [12]. 
Rifampin is absorbed when administered orally and it 
broadly distributed in body fluids and tissues. It 
metabolized in the liver [13]. 
 
Animal model use can use to study rifampicin: 
1. Physiologically Based Pharmacokinetic model 
2. Pharmacokinetic studies :  
A. Compartmental model  
I. Single or one compartmental 
model 
II. Multi Compartmental Model  
B. Non compartmental model 
3. Animal study 
Physiologically Based Pharmacokinetic model: 
In vivo evaluation of TB drug used against is 
performed through the study of correlations between 
drug exposure and efficacy data, is carried out on 
experimental calculation of maximum concentration 
reach into blood circulation (Cmax) [14]. Then the 
system consider a pharmacology approach, modeling 
to describe efficiently determine in vivo response of 
anti- TB drug needed for preclinical response of drug. 
Necessary information of drug-drug and host drug 
bacterial interactions, for these system the 
mathematical model used for the drug therapy tested 
against TB drug in mice model [15]. In these model 
reproduce the exploratory studies and generate 
hypotheses with regard the efficacy of drug regimens 
that are not initially tested. Whereas biological 
approach to testing immune response of 
mycobacterium tuberculosis infection in both human 
and in mice [16]. 
 
The pharmacokinetic model test limited to human 
disease.  Additionally, these PBPK models introduce 
little experimental data compared with other data 
obtained in animal models [17]. The mathematical tool 
required to support systems pharmacology framework 
for preclinical anti-tuberculosis drug evolution, we 
constructed whole body initial data of the in PBPK 
model of rifampicin. Now the treatment of TB requires 
the multiple drugs and mycobacterium tuberculosis is 
is potentially infect the tissue and whole body organs 
[18].  The pharmacokinetic model consist of 
rifampicin concentration in animal tissues and body 
fluids with various dose and routes of administration, 
were get from the  details of rifampicin in other 
animals and humans were used for model evolution 
while the corresponding data are not available [19]. No 
distinction was made for measurement of rifampicin 
concentration in serum and plasma when data obtained 
from other models such as high performance liquid 
chromatography (HPLC) or bioassay. 
 
Working of Physiologically Based 
Pharmacokinetic model (PBPK) ;  
The Physiologically based pharmacokinetic model 
was based on entire body structure be composed of 
perfusion-restricted section parameterized by blood 
flow rates, tissue volumes and drug-based on 
tissue/blood partition coefficients.  
 
After oral route of rifampicin was consisting as a 
pulsed input with 1st order absorption into the gut. 
Clearance of rifampicin through the kidney and liver. 
Clearance was describe in terms of total body 
clearance.   
 
Enterokinase circulation was utilizing a one-
compartment model for the gut lumen, with 1st order 
reabsorption into the gut and 1st order elimination in 
the feces. Blood flow and total clearance were based 
on three-fourth power of body weight. Model input 
consist of specified dosing regimen, set of parameter 
values and initial conditions of drug amount in every 
compartment. Model output consist of time dependent 
drug amount and concentration in blood and other 
tissues [19].    
 
Consequences of improper dosing of rifampicin:  
Rifampicin causes some times disturb stomach, 
heartburn, nausea, menstrual changes, drowsiness or 
dizziness. 
Rifampicin may cause convert the color of urine, 
saliva or tears, sweat in orange to red brown. This 
effect is safe occured when medication is stopped. 
However, teeth and contact lenses may be cause 
permanent staining [20]. 
Rifampicin may causes significant liver disease. This 
is necessary to completely treat the certain infection 
cause by rifampicin and it has treat by combination of 
other drugs such as isoniazid, pyrazinamide it may 
grow this risk [20]. Rifampicin may causes severe 
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intestinal state due to the variety of resistant bacteria. 
This condition may often cause during the treatment or 
weeks to months when treatment has stopped. 
 
Side effect of rifampicin : 
Headache, yellow color of eyes or skin, nausea and 
vomiting, dizziness, loss of appetite, unusual behavior, 
muscle pain, skin rash, weakness and abdominal pain.  
 
Drug resistance TB : 
The infective bacteria that leads tuberculosis can 
produce resistance to the antimicrobial drugs used 
to treat the tuberculosis [20]. Multidrug-resistant 
TB that doesn't retort to isoniazid and rifampicin 
drug that are most potent anti-TB drugs. The two 
reasons why multidrug resistance tuberculosis 
endures to emerge and spread are misconduct of 
TB treatment and aerobic transmission. Almost all 
of people having TB are treated by a six month 
treatment that is providing to patients with support 
and observation. Unsuitable or incorrect use of 
antimicrobial drugs, or use of unproductive 
formulations and premature treatment disruption 
can cause drug resistance, which can be then 
transmitted, particularly in congested area such as 
prisons and hospitals [21]. 
Drug-resistant TB can occur when the drugs used to 
treat TB are misused or mismanaged. Examples of 
misuse or mismanagement include 
 People do not complete a full course of TB 
treatment 
 Health care providers prescribe the wrong 
treatment (the wrong dose or length of time) 
 Drugs for proper treatment are not available 
 Drugs are of poor quality 
Type of drug resistant TB : 
1. Multidrug-resistant TB (MDR TB) 
2. Extensively drug- resistant TB (XDR TB) 
 
Multidrug-resistant TB (MDR TB) :  
Multidrug-resistant TB (MDR TB) is caused by TB 
bacteria that is resistant to at least isoniazid and 
rifampin, the two most potent TB drugs. These drugs 
are used to treat all persons with TB disease. TB 
experts should be consulted in the treatment of MDR 
TB. 
 
Extensively drug- resistant TB : 
Extensively drug-resistant TB (XDR TB) is a rare type 
of MDR TB that is resistant to isoniazid and rifampin, 
plus any fluoroquinolone and at least one of three 
injectable second-line drugs (i.e., amikacin, 
kanamycin, or capreomycin). 
Because XDR TB is resistant to the most potent TB 
drugs, patients are left with treatment options that are 
much less effective. 
XDR TB is of special concern for people with HIV 
infection or other conditions that can weaken the 
immune system. These people are more likely to 
develop TB disease once they are infected, and also 
have a higher risk of death once they develop TB [21] 
TB experts should be consulted in the treatment of 
XDR TB. 
Solutions to control drug-resistant TB are : 
 Provide the proper treatment to TB patient in 
first time around.  
 Provide the contact of TB patient to diagnosis.  
 Confirm sufficient infection to control in 
facilities where patients are treated.  
 Confirm the actual use of second-line drugs. 
 
 
Stability of rifampicin:  
Rifampicin should be stable at least minimum two 
years when it stored in desiccated -20°c and keep safe 
from light. Rifampicin is stable as a solidified at room 
temperature upto 70°c. 
 
Storage condition of rifampicin: 
 Avoid excessive heat (above 104º F) 
 Protect from light 
 Store at 77ºF; excursions permitted to 59-86ºF 
 Use within 24 hours from time of preparation 
Drug and food interaction: 
Rifampin and Alcohol: Drinking alcohol while taking 
rifampin may increase your risk of liver damage. 
Rifampin and Other Interactions: Rifampin may 
manufacture false-positive effect in urine screening 
tests for opiates. It can get involved with other 
laboratory tests, included in blood folate and vitamin 
B12 tests, liver and gallbladder function tests.   
 
 
Identification of rifampicin :  
pH : 4.5 to 6.5, determine in a 1.0 %w/v suspension 
[22] 
Assay : Determine by liquid chromatography 
Solvent mixture : A mixture of 10 volumes of 21.01 % 
w/v of citric acid, 23 volumes of a 13.61 %w/v 
solution of potassium dihydrogen phosphate, 77 
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volumes of a 17.42 % w/v solution of dipotassium 
hydrogen phosphate, 640 volumes of water and 250 
volumes of acetonitrile. 
 
Test solution: weigh quantity of powder containing 20 
mg substance under the examination in 10 ml of 
acetonitrile, shake and filter. Dilute 5 ml of filtrate to 
100 ml with the solvent mixture. 
Reference solution: A solution containing 0.02 % w/v 
of rifampicin RS in acetonitrile and filter. Dilute 5 ml 
of this solution to 100ml with solvent mixture. 
Chromatographic system: A stainless steel column 10 
cm * 4.6 mm packed with octylsilane bonded to 
porous silica. 
Mobile phase : A mixture of 65 volumes of a solution 
containing 0.1 % v/v orthopohosphoric acid, 0.19 % 
w/v sodium perchlorate, 0.59 % w/v of citric acid and 
2.09 %w/v potassium dihydrogen phosphate and 35 
volumes of acetonitrile,  
Flow rate of column was 1.5 ml/min. 
spectrophotometer set at 254 nm and injection volume 
20µl [22]. 
Inject the reference solution. The test is not valid 
unless the relative standard deviation for the replicate 
injections is not more than 2 %. Inject the reference 
solution and test solution. Calculate the content of 
rifampicin. 
Loss on drying: 
Not more than 1%, determine on 1 g by drying In an 
oven at 80º at a pressure not exceeding 0.7 kPa for 4 
hours22 
Thermal study of rifampicin polymorphs: 
Rifampicin exist as a two form such as polymorph I 
and polymorph II. The polymorph I is most stable 
while polymorph II are meta stable. As well as these 
two principle form is found as hydrate and solvate, 
which change in amorphous form after removal of 
solvent. 
 
Differential Scanning Calorimetry: 
The DSC curves were getting on a DSC- 50 cell 
utilizing aluminium crucibles with 2 mg weight of 
sample, under the dynamic N2 atmosphere with the 
rate of 50 mL min-1 and heating rate of 10°C min -1 
between 25 to 500°C.  
 
The thermal measures observed on the DSC curve 
according to mass losses showed on TG/DTG/DSC 
curves. The DSC curve showed an endothermic peak 
with heat variation starting at 183 - 188ºC. The 
endothermic peak which occurred at 184.69ºC is the 
characteristics of a melting process followed by 
recrystallization, which is later characterized by 
exothermic peak starting at 245 - 420°C. The 
exothermic peak which occurred at 245.29 °C having 
melting point23. The thermal decomposition process 
peak started with heat liberated from recrystallization 
which make polymorph I and continued exothermally. 
 
 
Fig 2: DSC thermogram of Rifampicin polymorph I and polymorph II 23 
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Fourier transform infrared spectroscopy (FTIR) of 
polymorph I and polymorph II :  
FTIR spectrum of form I of Rifampicin, getting with a 
resolution of 4 cm−1 in the region 4000-650 cm−1, 
where the major absorption bands characterizing this 
drug are detected23,24. The dissimilar crystal packing 
of rifampicin, assign to the different possibilities of 
hydrogen bonding, conformational exchanges, and 
ionization states, is the clearest evidence of its 
polymorphism. All the functional class that can be 
include in H bonding are intra molecularly bonded, 
also confirmed by our X-ray analysis, acetyl group, be 
visible differences in OH of the chain loop,  furanone 
group and amide C=O frequencies. Such differences 
are main to distinguish polymorphic forms of 
rifampicin.  
In Fig.3 shows the ranges of both polymorphs.  
 
 
 
Fig 3 FTIR Spectra of polymorph I and polymorph II 23, 24 
 
Table 3 : FTIR spectra of rifampicin form I 
 
Standard peak cm-1 
 
Observed peak cm-1  
 
Functional group 
 
3400-3200 3400 Ansa OH 
1725-1700 1722 Acetyl C=O 
1680-1630 1643 Furanone C=O 
 
 
Table 4 : FTIR spectra of rifampicin form II 
 
Standard peak cm-1 Observed peak cm-1  
 
Functional group 
 
3400-3200 3356 Ansa OH  
1750-1730 1732 Furanone C=O 
1725-1700 1714 Acetyl C=O 
 
Thermogravimetric Analysis (TGA): 
Thermogravimetric analysis (TGA) (Mettler-Toledo, 
Greifensee, Switzerland) was applied to get the weight 
forgetting and breaking up temperature of 
polymorphs. TGA curve were present with on 851e 
Mettler Toledo with heating rate10°C/min and 
atmosphere of  N2 flow rate: 50mL/min. The 
equipment was calibrated with indium and aluminum 
[25,26].  
 
The rifampicin polymorphs were examined from 
298.15 to 573.15 K at heating rate of 10 K/min below 
the defence of nitrogen gas27. In TGA analysis, no 
weight forgetting upto 190ºC has specified the absence 
of either solvate or hydrate in standard as well as trade 
samples. In the graph of TGA curve form I occurred at 
the themperature 224.17 ºC and form II showed the 
temperature at 194.04 ºC 
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Fig 4 : Thermogravimetric analysis of polymorph I and polymorph II25, 26 
Powder X-Ray Diffraction : 
Powder X-ray diffraction (PXRD) was used to test the polymorphic forms of solid-state rifampicin. The details were 
obtained on Rigaku D/ max-2500 (Rigaku, Japan) utilizing Cu-Ka radiation (0.15405 nm) with electric current of 100 
mA, and voltage of 40 kV. The samples were inspect above diffraction angle (2q) from 2 to 30 at step size of 0.02 and 
scanning rate of 8 min-1. 
  
Polymorphic forms I and II were readily detectable from their p-XRD patterns which are shown in Fig 5. The 
characteristic peaks for form I were seen at 13.65 and 14.35º 2θ, whereas form II present at 9.93 and 11.10º 2θ [27]. 
 
 
                                        Fig 5. : PXRD Spectra of polymorph I and polymorph II 27 
 
Analytical method of rifampicin :  
 
Thin layer chromatography: 
TLC has been used in field of rifampicin and colored 
spots are directly located. Many TLC procedure were 
developed for analysis of rifampicin and it’s 
metabolites body fluids. The RF values were shown to 
be dependent on the concentration. The spots were 
quantitiated by using the bioautographic technique, 
densitometric, visual estimation or by the elution 
method by microbiological aasay. A stationary phase 
partition TLC procedure has been describe for the 
determination of rifampicin. Silica gel plates were 
used as stationary phase, phosphate buffer pH 7 
containing 0.1% sodium ascorbate as mobile phase. 
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The colored spot was eluted and measured 
spectrometrically [28] 
 
Column chromatography :  
The content of rifampicin and it’s metabolites in urine, 
bile and serum was determine by extraction with 
chloroform and by column chromatography followed 
by spectrophotometry. The liquid- solid 
chromatography was carried out using glass column 7 
cm long, 4 mm internal diameter, packed with silica 
gel G, buffered at pH 6 and chloroform and 
chloroform- methanol in pregressively increasing 
amount as solvent, at a flow rate of 0.15 ml/min. 
Rifampicin and its metabolites were quantified by 
reading the absorbance of the eluates at specific 
wavelength [28] 
 
Paper chromatography :  
A paper chromatographic technique for determination 
of rifampicin and 25- deacetylrifampicin was used foe 
urine and bile. Was carried out on whatman 3mm 
paper using methanol : n- octanol as stationary phase 
and aqueous buffer, pH 6, as mobile phase for  hours. 
The intensity of the red-orange spots was measured by 
an analytrok photodensitometer or material 
determined bioautographically. Paper 
chromatographic method for the separation of 
rifampicin and its metabolites using ethyl acetate- 
water- dimethylformamide (10:10:1) [28] 
 
High pressure liquid chromatography :  
Drug content and dissolution samples were analysed 
using an HPLC system with UV detection. 
Chromatography was performed using a Bondapak 
C18 10 mm 3.9 ¥ 300 mm column (Waters) and a 
SecurityGuard  guard column. The mobile phase, 
consisting of methanol–acetonitrile-phosphate buffer 
solution (pH 5.2), 50:17:33, was eluted at a flow rate 
of 1.2 ml/min, and the UV detector was set to drug 
wavelength. The column temperature was maintained 
at 25°C and the volume of each sample injected was 
50 ml2 
 
Marketed formulation :  
 
Formulations Dosage forms Manufacturer 
Rifampicin 150 mg Tablet  Hetero healthcare PVT 
LTD 
Rifampicin 450 mg Capsule Lupin LTD 
Rifacip 150 mg Capsule Cipla Ltd 
Rifampin 600mg/ 10ml Injection, lyophilized 
powder 
Akorn LTD 
Tibrif 450 mg Tablet  Agron remedies PVT. 
LTD 
Rimpin 150 mg  Capsule  Hetero healthcare LTD 
Rimactane 200 ml Syrup  Novartis INDIA LTD 
Rifit 200ml Syrup  Finecure 
pharmaceuticals 
Rifalone 450 mg Tablet  Medispan LTD 
Rifampicin 300 mg  Capsule  Lupin LTD  
Monocin 600 mg Tablet  Overseas healthcare PVT 
LTD  
Rifalite 450 mg  Capsule Elite pharma PVT LTD 
Rifit 650 mg  Tablet  Finecure 
pharmaceuticals 
Rifampicin (300 mg) + isoniazid (150 mg) Capsule  Sanofi- Aventis 
Rifampicin(120 mg) + isoniazid (50 mg)+ 
pyrazinamide(300 mg) 
Tablet  Remedy repack 
Rifampicin (300mg) + Isoniazid (50 
mg) + Pyrazinamide (120 mg) 
Tablet  Sanofi- Aventis 
Rifampicin 300 mg + Isoniazid 150 mg Capsule  Sanofi- Aventis 
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Routes of administration, dose and Effectiveness of rifampicin : 
 
Dose Routs of administration Effectiveness 
600 mg (adult) Oral administration  Peak serum concentration was 32 
mcg/ml 
300 mg (adult) IV administration Mean plasma concentration of 
rifampicin upto 8 hr was 1.1±0.6 
mcg/ml 
600 mg (adult) IV administration Mean plasma concentration of 
rifampicin upto 12 hr was 1.2±0.6 
mcg/ml 
10 mg/kg body weight (pediatric) Oral administration mean peak serum concentrations of 
3.5 mcg/mL 
10 mg/kg body weight (pediatric) IV administration mean peak serum concentration of 
rifampin at the end of a 30-
minute was 25.9±1.3 mcg/mL 
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